FDA Authorizes Lilly’s Bebtelovimab for Some Covid Treatment

FDA issues emergency use authorization for Eli Lilly’s bebtelovimab to treat mild to moderate Covid-19 in adults and some pediatric patients.

• Bebtelovimab is a new monoclonal antibody that retains activity against the omicron variant
• Pediatric use is for patients 12 years of age and older weighing at least 40 kilograms, about 88 pounds
• Bebtelovimab is not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy due to Covid-19
• NOTE: U.S. Agrees to Pay Lilly $720 Million for New Covid Treatment

To view the source of this information, click here

To contact the reporter on this story: ...